# Diabetes Mellitus Screening

Screen adults and selected youth for dysglycemia using validated plasma glucose or A1C testing, confirm abnormal results when hyperglycemia is not unequivocal, and recognize settings—including HIV and pediatric risk—in which test selection and interpretation require modification.

**Clinical question:** Who should be screened for diabetes, which test should be ordered, and how should abnormal results be confirmed?

Updated: 2026-08-20T23:53:33.109001Z

## What matters in practice
- ADA-supported screening begins at age 35 years for asymptomatic adults; A1C, fasting plasma glucose, and 2-hour 75-g OGTT are accepted screening tests.[8]
- Diabetes is diagnosed by A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL, or 2-hour plasma glucose at least 200 mg/dL during a 75-g OGTT; an abnormal result should be repeated when hyperglycemia is not unequivocal.[10]
- In people with HIV receiving ART, use plasma glucose rather than A1C to diagnose diabetes because A1C may underestimate dysglycemia; obtain random or fasting glucose at entry to care and annually thereafter.[10]
- Screen asymptomatic youth at risk for type 2 diabetes or prediabetes; ADA and AAP endorse screening in this population.[11]

## Who should be screened

Screening applies to asymptomatic people; diagnostic testing is indicated when symptoms or marked hyperglycemia are present.

The ADA proposes healthcare-setting screening for all asymptomatic adults aged 35 years or older.[8] Available search evidence does not provide a complete risk-factor-based earlier-screening algorithm, pregnancy screening protocol, rescreening interval, or stopping rule; consult current ADA Standards for those decisions.

ADA and AAP recommend screening asymptomatic youth for type 2 diabetes and prediabetes.[11] The supplied evidence does not specify the pediatric eligibility criteria or testing interval; use current pediatric guidance to determine which children and adolescents meet risk-based screening criteria.

*Screening populations supported by supplied guidance.[8][11]*

| Population | Screening approach supported by supplied evidence | Important limitation |
| --- | --- | --- |
| Asymptomatic adults aged 35 years or older | Screen in a healthcare setting with A1C, fasting plasma glucose, or 2-hour 75-g OGTT.[8] | The supplied results do not specify repeat interval or earlier adult risk-based criteria. |
| Asymptomatic youth at risk for type 2 diabetes or prediabetes | ADA and AAP recommend screening.[11] | Risk criteria, preferred test, and interval are not detailed in the supplied result. |

## Choose a validated glycemic test

Use venous plasma glucose or laboratory A1C; each assay detects a different glycemic phenotype.

Diabetes may be diagnosed by elevated venous plasma glucose or elevated hemoglobin A1C.[7] The accepted diagnostic thresholds cited in the supplied guidance are fasting plasma glucose at least 126 mg/dL (7.0 mmol/L), 2-hour plasma glucose at least 200 mg/dL (11.1 mmol/L) after a standard 75-g OGTT, or A1C at least 6.5%.[10]

A1C, fasting plasma glucose, and 2-hour OGTT are all proposed screening options for asymptomatic adults.[8] Test selection should be driven by clinical practicality and the likelihood of misleading A1C interpretation. A1C alone identifies only a minority of diabetes cases identified collectively by A1C and glucose-based criteria, underscoring that discordance between assays is clinically meaningful rather than exceptional.[22]
- Order fasting plasma glucose when a fasting specimen is feasible and a plasma glucose-based diagnosis is desired.[10]
- Use a 2-hour 75-g OGTT when postchallenge dysglycemia is a concern or when clarification is needed after discordant screening results; diabetes is diagnosed at a 2-hour value of at least 200 mg/dL.[10]
- Use A1C only when its interpretation is reliable for the individual patient; the diagnostic threshold is at least 6.5%.[10]

*Diagnostic thresholds for diabetes mellitus.[10]*

| Test | Diabetes threshold | Operational note |
| --- | --- | --- |
| Fasting plasma glucose | At least 126 mg/dL (7.0 mmol/L).[10] | Use venous plasma glucose criteria. |
| 2-hour plasma glucose after 75-g OGTT | At least 200 mg/dL (11.1 mmol/L).[10] | Requires a standard 75-g glucose load. |
| A1C | At least 6.5%.[10] | May be misleading in people with HIV receiving ART.[10] |

## Confirm abnormal screening results and resolve discordance

Repeat testing is essential unless the clinical presentation establishes diabetes unequivocally.

When A1C and fasting glucose are discordant in people with HIV, the cited ADA approach is to repeat the abnormal test and diagnose diabetes only if the repeat result remains above the diagnostic cutoff.[10] This confirmation principle is particularly important when screening detects isolated, modest abnormalities rather than unequivocal hyperglycemia.

A random glucose greater than 200 mg/dL in people with HIV should trigger further evaluation with fasting blood glucose.[10] The supplied sources do not provide a general-population random-glucose diagnostic pathway or symptom-based exception to confirmation; follow current ADA diagnostic guidance for those scenarios.
- Do not assume a normal A1C excludes diabetes when glucose results are abnormal or when a condition may distort A1C interpretation.[10][22]
- Repeat an abnormal result rather than averaging discordant values; the diagnosis requires persistence of an abnormal result in the setting described above.[10]
- For an abnormal random glucose in a person with HIV, obtain fasting plasma glucose rather than relying on A1C for diagnosis.[10]

*Practical response to common screening-result patterns.[10][22]*

| Result pattern | Next action | Rationale |
| --- | --- | --- |
| A1C and fasting glucose are discordant in a person with HIV | Repeat the abnormal test; diagnose diabetes only if repeat testing remains above its diagnostic cutoff.[10] | A1C may underestimate dysglycemia in people with HIV receiving ART.[10] |
| Random glucose above 200 mg/dL in a person with HIV | Obtain fasting blood glucose.[10] | Plasma glucose criteria are preferred for diagnosis after ART initiation.[10] |
| Normal A1C but abnormal glucose-based test | Do not dismiss the glucose abnormality; pursue glucose-based confirmation as appropriate.[10][22] | A1C alone has limited sensitivity relative to combined A1C and glucose-based case ascertainment.[22] |

## Screening in people with HIV

ART and HIV-related factors can make A1C an unreliable diagnostic test.

Among people with HIV, A1C is highly specific but insensitive for diabetes diagnosis and can underestimate diabetes risk.[10] The HIVMA/IDSA guidance reports that ADA standards recommend against using A1C to diagnose diabetes in people with HIV receiving ART; after ART initiation, use plasma glucose criteria for diagnosis.[10]

Obtain random or fasting glucose and A1C before starting ART. At entry to HIV care and annually thereafter, obtain either random or fasting glucose; if random glucose is abnormal, obtain fasting glucose.[10] A1C may still be followed in patients with established diabetes, but correlate it with measured glucose because ART may cause over- or underestimation on an individual basis.[10]
- At HIV entry to care: obtain random or fasting glucose and A1C before ART.[10]
- After ART initiation: use plasma glucose criteria for diabetes diagnosis.[10]
- For established diabetes: monitor A1C at least every 6 months, with an A1C goal below 7% cited by HIVMA/IDSA in accordance with ADA guidance, while individualizing interpretation against glucose values.[10]

*HIV-specific approach to diabetes screening and diagnosis.[10]*

| Clinical moment | Recommended measurement | Interpretive action |
| --- | --- | --- |
| Before ART | Random or fasting glucose plus A1C.[10] | Establish baseline; recognize that A1C may not reliably represent glycemia. |
| Entry to care and annually thereafter | Random or fasting glucose.[10] | If random glucose is abnormal, obtain fasting glucose.[10] |
| After ART initiation | Plasma glucose criteria for diagnosis.[10] | Avoid diagnosing diabetes solely from A1C.[10] |
| Established diabetes | A1C at least every 6 months.[10] | Assess concordance with glucose before applying an individual A1C target.[10] |

## Presymptomatic type 1 diabetes screening remains selective

Islet autoantibody screening is not yet routine population practice.

The principal goal of type 1 diabetes screening programs in youth is to reduce diabetic ketoacidosis at diagnosis and support research participation.[17] However, type 1 diabetes screening is still conducted primarily in research-based settings, and real-world testing remains inconsistent.[19]

An analysis from the ASK study suggests that autoantibody screening may be cost-effective in areas with high diabetic ketoacidosis rates, but the supplied evidence does not establish a universal U.S. population-screening recommendation, testing panel, or surveillance schedule.[9]
- Consider referral to an established type 1 diabetes screening or research program when family history, patient preference, or local program availability makes autoantibody testing actionable.[17][19]
- Do not substitute presymptomatic type 1 diabetes autoantibody testing for standard glucose-based screening for type 2 diabetes or dysglycemia.[8][19]

## Common questions

### Which tests can be used to screen asymptomatic adults for diabetes?

A1C, fasting plasma glucose, and 2-hour plasma glucose after a 75-g OGTT are accepted screening tests for asymptomatic adults.[8] Diabetes thresholds are A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL, and 2-hour OGTT glucose at least 200 mg/dL.[10]

### Should a single abnormal screening test establish diabetes?

When results are not unequivocal, repeat the abnormal assay for confirmation. In people with HIV with A1C-glucose discordance, diabetes should be diagnosed only when repeat testing remains above the diagnostic cutoff.[10]

### Is A1C appropriate for diabetes diagnosis in people with HIV?

Not as the preferred diagnostic test after ART initiation. HIVMA/IDSA cites A1C insensitivity and recommends plasma glucose criteria; obtain random or fasting glucose at entry to care and annually, with fasting glucose after an abnormal random result.[10]

### Should asymptomatic youth be screened for diabetes?

Yes, ADA and AAP recommend screening asymptomatic youth for type 2 diabetes and prediabetes, although the supplied result does not provide detailed risk criteria or intervals.[11]

## References
1. - IIER - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf
2. Garzulys - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761497s000lbl.pdf
3. Diagnosis and Screening of Pediatric Diabetes Mellitus — www.nature.com — https://www.nature.com/nature-index/topics/l4/diagnosis-and-screening-of-pediatric-diabetes-mellitus
4. Diagnostic Methods for Diabetes and Glucose Metabolism — www.nature.com — https://www.nature.com/nature-index/topics/l4/diagnostic-methods-for-diabetes-and-glucose-metabolism
5. Treatment of Diabetes in Older Adults: An Endocrine ... — academic.oup.com — https://academic.oup.com/jcem/article/104/5/1520/5413486
6. Physician Process and Patient Outcome Measures... : Medical Care — journals.lww.com — https://journals.lww.com/lww-medicalcare/fulltext/2004/09000/physician_process_and_patient_outcome_measures_for.3.aspx
7. Executive Summary: Guidelines and Recommendations for ... — academic.oup.com — https://academic.oup.com/clinchem/article/69/8/777/7226243
8. Guidelines and Recommendations for Laboratory Analysis ... — academic.oup.com — https://academic.oup.com/clinchem/article/69/8/808/7226244
9. Establishing Screening Programs for Presymptomatic Type 1 ... — academic.oup.com — https://academic.oup.com/jcem/article/110/8/2371/8103687
10. Primary Care Guidance for Persons With HIV — www.idsociety.org — https://www.idsociety.org/practice-guideline/primary-care-management-of-people-with-hiv
11. Screening and Diagnosis of Prediabetes and Diabetes in ... — publications.aap.org — https://publications.aap.org/pediatrics/article/146/3/e20200265/36758/Screening-and-Diagnosis-of-Prediabetes-and
12. U.S. Selected Practice Recommendations for ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.15585%2Fmmwr.rr7303a1&link_type=DOI
13. Diabetes Mellitus — publications.aap.org — https://publications.aap.org/books/chapter-pdf/795344/aap_9781581106244-part02-diabetes_mellitus.pdf
14. 10. Cardiovascular Disease and Risk Management — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S010&link_type=DOI
15. 11. Chronic Kidney Disease and Risk Management — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S011&link_type=DOI
16. 2. Diagnosis and Classification of Diabetes: Standards of Care ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2FDC25-S002&link_type=DOI
17. Screening Programs for Type 1 Diabetes in Youth — publications.aap.org — https://publications.aap.org/pediatrics/article/157/6/e2025075728/207530/Screening-Programs-for-Type-1-Diabetes-in-Youth
18. Prioritizing Health | Diabetes, Diet and GLP-1 RAs — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2025/06/01/01/prioritizing-health-diabetes-diet-and-glp-1-ras
19. Type 1 Diabetes Screening in Pediatrics — publications.aap.org — https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting
20. Guidelines and Clinical Policy — www.acc.org — https://www.acc.org/guidelines
21. Follow-up Report on the Diagnosis of Diabetes Mellitus — diabetesjournals.org — https://diabetesjournals.org/care/article/26/11/3160/22281/Follow-up-Report-on-the-Diagnosis-of-Diabetes
22. 2. Classification and Diagnosis of Diabetes: Standards of ... — diabetesjournals.org — https://diabetesjournals.org/care/article/43/Supplement_1/S14/30640/2-Classification-and-Diagnosis-of-Diabetes
23. Diagnosis and Classification of Diabetes Mellitus — diabetesjournals.org — https://diabetesjournals.org/care/article/37/Supplement_1/S81/37753/Diagnosis-and-Classification-of-Diabetes-Mellitus
24. Tests for Screening and Diagnosis of Type 2 Diabetes — diabetesjournals.org — https://diabetesjournals.org/clinical/article/27/4/132/1673/Tests-for-Screening-and-Diagnosis-of-Type-2

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.